The new and contagious XEC COVID-19 variant is spreading rapidly in several countries. Will it cause a surge in the U.S.?

The monovalent XBB.1.5 COVID-19 vaccine is effective against XBB and JN lineage hospitalization; however, protection against the latter may be attenuated.

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...

For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club – a term ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

With the U.S. Food and Drug Administration and Centers for Disease Control and Prevention approval of new mRNA COVID-19 ...

The Workers Party government has failed to inform the population about the latest wave of the pandemic in Brazil, while ...

Vaxxas today announced that it has initiated a multi-center Phase I clinical trial of a vaccine against pre-pandemic avian ...

The new "XEC" COVID-19 variant spreading rapidly in Europe has arrived in the US. What are the symptoms, will it cause a fall ...